Viatris Addresses Supply Demand for Estradiol Products
Viatris reported a significant surge in demand for its estradiol patches and creams and detailed steps taken to increase production capacity.
Stocks · News reference
JPMorgan Adjusts Viatris Price Target to $20
JPMorgan Chase has raised its price target for Viatris Inc. from $18 to $20 while maintaining a neutral rating on the stock.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Piper Sandler Adjusts Price Target on Viatris to $14 From $13
Piper Sandler has updated its price target for Viatris Inc., raising it from $13 to $14.
Viatris Receives FDA Approval For RYZUMVI To Treat Presbyopia In Adults
Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in